Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for depression in Parkinson's disease
2018-004112-21Phase 4Completed
- Sponsor
- IRCCS San Raffaele Pisana
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD) and Parkinson's disease (PD), sponsored by IRCCS San Raffaele Pisana. Primary endpoints: Safety and Tolerability. Started Jun 2021; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-004112-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004112-21.